Fredrik Ollila, PhD (Biochemistry)
Chief Executive Officer
Dr. Ollila has a cross-functional background. He obtained his doctorate in biochemistry from Åbo Akademi University, Finland and has also studied Marketing and Finance at the Business School in Turku, Finland. Between 2003 and 2006 he held several positions at Novartis Pharma AG in Basel, Switzerland with increasing levels of responsibility. Dr. Ollila managed the FiberLive technology at Vivoxid Ltd. between 2006 and 2008, and from March 2008 he was responsible for the Global Sales and Marketing of BonAlive® at Vivoxid Ltd. Dr. Ollila was the key architect in executing the management buy-out of the BonAlive® technology from Vivoxid Ltd in 2009 and he has been the CEO of
the company since then.
Jimmy Lucchesi, BSc (Engineering)
Chief Operating Officer
Mr. Lucchesi has served three life science companies for the last 10 years in managerial positions and during that period he has gained comprehensive knowledge of design development, business development and manufacturing of medical devices. Prior to this, Mr. Lucchesi worked as a research scientist at the University of Helsinki. He was employed by Vivoxid in 2006 as Business Development Manager and joined the newly formed company BonAlive Biomaterials Ltd in 2010.
Satu Lindgren, MSc (Chemistry)
Director, Quality, Regulatory and Clinical
Mrs. Lindgren joined BonAlive Biomaterials Ltd in 2010 having previously served Vivoxid Ltd since 2001. She has experience in leading projects and regulatory issues in various medical device and diagnostics companies. She has a profound knowledge of quality management, risk management, registration and validation.